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Low diastolic blood pressure, hypoalbuminemia, and risk of death in a
cohort of chronic hemodialysis patients. In a previous report, we showed
that nutritional status and especially serum albumin had great predictive
value for death in chronic hemodialysis patients, whereas blood pressure
did not. In the present study, we analyzed the causes of death in
consideration of the relationship between serum albumin and blood
pressure. A total of 1,243 Okinawan patients (719 males, 524 females)
undergoing hemodialysis in January 1991 were followed up through the
end of 1995. Three hundred forty-two of the patients died, 45 received
transplants, and 12 were transferred by the end of the follow-up period.
The total duration of observation was 5,110.3 patient-years. Blood pres-
sure as well as clinical and laboratory variables were determined imme-
diately prior to the first dialysis session in January 1991. The crude death
rate was 40.0% when the diastolic blood pressure (DBP) <70 mm Hg,
35.0% at 70 to 79 mm Hg, 25.0% at 80 to 89 mm Hg, 25.0% at 90 to 99
mm Hg, and 13.0% at >100 mm Hg. The death rate showed an inverse
correlation with DBP. DBP showed a significant positive correlation with
serum albumin (r = 0.137, P < 0.001) and age (r = —0.325, P < 0.0001).
The adjusted odds ratio (95% confidence interval) of death was 0.84 (0.71
to 0.99) with 10 mm Hg increments in DBP when the reference DBP was
less than 69 mm Hg. Low DBP may be a manifestation of malnutrition
and/or cardiovascular disease in chronic hemodialysis patients. Target
DBP levels may be higher levels in chronic hemodialysis patients than the
general population.
The prognosis of chronic dialysis patients is poor compared to
that of the general population [1]. Therefore, every effort must be
made to detect potentially treatable causes of death in such
patients. Charra et al. reported that the best survival was associ-
ated with control of both nutritional factors and blood pressure [2,
31. Nutritional factors have been shown to be a strong predictor of
mortality in chronic dialysis patients [4, 5]. However, Churchill et
al [6] found that the effects of blood pressure on survival were not
significant as did the present authors [4]. Recently, an increasing
number of elderly and sick patients have been accepted for
dialysis [1, 7]. The level to which blood pressure should be
lowered is still under debate, even in the general population [8]. In
dialysis patients, who are highly selected and have multiple
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comorbid conditions, data that assess the relative contribution of
each risk factor are lacking [9, 10].
The aim of the present study was to determine the relationship
between the baseline levels of serum albumin and blood pressure,
and to analyze the causes of death in chronic dialysis patients. We
focused on the effects of these variables on the survival of the
patients. Target blood pressure levels were determined with
respect to the mortality rate. The results confirm the significance
of hypoalbuminemia and low diastolic blood pressure on survival.
Methods
A total of 1,243 patients (719 males, 524 females) undergoing
hemodialysis in January 1991 in Okinawa, Japan were examined
and prospectively followed up until the end of 1995. The demo-
graphics of this patient population were reported previously [1,41.
Briefly, patients with end-stage renal disease who survived at least
one month on dialysis were registered in the Okinawa Dialysis
Study (OKIDS) registry. Between 1971 and 1990, a total of 1,982
patients were registered (824 females and 1,158 males). Patients
who died (N = 605), underwent renal transplant (N = 75), were
transferred (N = 23), or were placed on CAPD (N = 36) were
excluded. All outcomes were known and confirmed. Frequency of
dialysis was 0.9% once-weekly, 15.4% twice-weekly, and 83.7%
thrice-weekly [4]. Baseline data of laboratory and clinical vari-
ables were obtained before the first dialysis session in January
1991. Similarly, the baseline blood pressure was recorded in order
to establish a pre-dialysis blood pressure in January 1991. Mean
arterial blood pressure (MAP) was calculated as diastolic blood
pressure (DBP) +1/3[systolic blood pressure (SBP) — DBP].
Administration of antihypertensive drugs was confirmed by
reviewing patient charts. Antihypertensive drugs were categorized
as follows: calcium channel blockers, ACE inhibitors, beta-block-
ers, centrally acting drugs, alpha-blockers, and vasodilators. Di-
uretics were not included. Six hundred and forty-six patients
(52.0%) were prescribed at least one antihypertensive drug. In the
patients receiving antihypertensives (N = 646), calcium channel
blockers were used in 552 patients (80.8%), ACE inhibitors in 216
patients (33.4%), beta blockers in 159 patients (24.6%), centrally
acting agents in 77 patients (11.9%), alpha blockers in 45 patients
(7.0%), and vasodilators in 22 patients (3.4%).
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Fig. 1. Cumulative incidence of death in cohort of 1,243 chronic hemodi-
alysis patients. The follow-up period was 1991 through 1995. Figures are
number of patients at risk.
Causes of death were categorized as: infection, withdrawal,
cardiac, sudden death, vascular, and others [1, 11]. Briefly, the
final decision was made by one of the author (K.!.) by reviewing
the medical charts and after discussion with the physician. Vas-
cular death was restricted only those who had X-ray, CT brain
scan, and laboratosy data. In case of long-term hospitalization,
direct cause of death was taken for the cause of death. All patients
were followed up until death, renal transplantation, transfer
outside of Okinawa, or the end of 1995. The number of deaths,
transplants, and transfers were 342, 45, and 12, respectively. The
total duration of observation was 5,110.3 patient-years.
Statistical analysis was performed with the SAS package using
the database of the Okinawa Dialysis Study (OKIDS) [1,
Student's 1-tests and chi square tests were used. Pearson correla-
tion coefficients were calculated in order to investigate the
relationships between the pertinent clinical variables. Multiple
logistic analysis was performed in order to determine the signifi-
cance of each variable with respect to survival. Survival curves
were drawn by the Kaplan-Meier method. P values less than 0.05
were considered statistically significant. Data were expressed as
mean SEM.
Results
Figure 1 shows the cumulative incidence of death. Death
increased linearly over time, and reached 28.3% of five years. The
total number of deaths was 342 (200 men and 142 women); 78
(22.8%) cardiac, 62 (18.1%) infection, 56 (16.4%) withdrawal, 26
(7.6%) sudden death, 67 (19.6%) vascular, and 53 (15.5%) other
causes. In these categories, cardiac, withdrawal, sudden death,
and vasucular death are basically cardiovascular origin.
Table I shows the baseline variables of patients who died and
who survived. In the deceased group, age was greater and
duration of hemodialysis was shorter, whereas the dose of dialysis
was lower than that in the survival group. Body height and weight
were significantly lower in the deceased group. No significant
difference between the groups was observed in systolic blood
pressure, but diastolic blood pressure was significantly lower in
the deceased group. Total protein, serum albumin, total choles-
terol, triglyceride, BUN, and serum creatinine were also signifi-
Table 1. Comparison of the baseline variables between patients who
died and who survived which were obtained at the entry to the study
(January 1991)
Patients who received renal transplantation (N = 45) or were trans-
ferred outside Okinawa (N = 12) during the study period were excluded.
Numbers in parentheses denote SEM. Ahbrevations are: HD, hemodialysis;
BP, blood pressure; BUN, blood urea nitrogen; NS, not significant.
Duration of HD refers to how long the patients had been on dialysis prior
to entry into the study.
P Value is died vs. survived.
cantly lower in the deceased group. Survivors and died patients
had a similar percent of use of antihypertensives. Comparison of
clinical variables between those who were receiving once or twice
dialysis per week and those on thrice per week were summarized
in Table 2. Women were more common in those who were
dialyzed less than three times per week. There was no difference
in serum albumin and death rate between the groups.
Table 3 shows the mean (SEM) levels of systolic and diastolic
blood pressure in each baseline serum albumin category. A
significant correlation between baseline serum albumin and dia-
stolic blood pressure was observed (r = 0.137, P = 0.0001). The
proportion of renal transplantation and transferral outside of
Okinawa were higher in patients with normal serum albumin.
Table 4 shows the death rate and mean (5EM) age of the patients
in each systolic, diastolic, and mean arterial pressure category.
The death rate and diastolic blood pressure were inversely
correlated. Since the number of patients with SBP less than 119
mm Hg was small, all such patients were considered together.
Table 5 shows the number (%) of deaths at each level of
baseline serum albumin. In patients with hypoalbuminemia (less
than 3.5 g/dI) the most common causes of death were withdrawal
and cardiac. In normo-albuminemia patients (greater than 4.0
g/dl), vascular and infection were the leading causes of death.
Figure 2 shows the survival curves in relation to the baseline
levels of serum albumin. In patients with hypoalbuminemia, the
five-year proportion of survival was less than 50%. The survival
curves for each baseline level of systolic and diastolic blood
pressure are shown in Figures 3 and 4. No appreciable differences
were observed among the subgroups of SBP. Higher baseline
DBP levels were associated with a high proportion of survival.
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Age years
Duration of HD months
Dose of dialysis m2hr/W
Body height meters
Body weight kg
Body mass index kglm2
Systolic BP mm Hg
Diastolic BP mm Hg
Total protein g/dl
0 12 24 36 48 60 Serum albumin gidITotal cholesterol mg/dl
Triglyceride mg/dl
BUN mg/dl
Serum creatinine mg/dl
Serum uric acid mg/eli
Smoker %
Drinker %
Diabetes mellitus %
Antihypertensives %
Male %
Total Died
Clinical N = 1,186 N = 342
52.4 (0.4) 62.9 (0.7)
62.4 (1.5) 54.4 (2.6)
18.2 (0.2) 16.4 (0.3)
1.56 (0.01) 1.54 (0.01)
53.0 (0.3) 50.6 (0.5)
21.6 (0.1) 21.4 (0.2)
151.5 (0.7) 152.3 (1.3)
80.8 (0.4) 77.1 (0.7)
6.5 (0.02) 6.4 (0.03)
3.9 (0.01) 3.7 (0.03)
171.1 (1.2) 164.2 (2.2)
161.9 (3.1) 141.6 (5.0)
85.8 (0.6) 82.2 (1.1)
13.1 (0.1) 11.4 (0.2)
8.2 (0.1) 8.1 (0.1)
23.4 20.5
20.3 12.3
17.6 35.4
51.7 53.2
58.1 55.3
Survived
N 844 P Valued
48.8 (0.5) 0.000t
65.6 (1.8) 0.0004
19.0 (0.2) 0.0001
1.57 (0.01) 0.0001
54.0 (0.4) 0.0001
21.7 (0.1) NS
151.2 (0.8) NS
82.3 (0.5) 0.0001
6.6 (0.02) 0.0001
4.0 (0.02) 0.000 1
173.8 (1.4) 0.0002
170.2 (4.3) 0.0001
87.2 (0.7) 0.000 1
13.8 (0.1) 0.0001
8.3 (0.1) NS
24.6 NS
23.6 0.0001
10.4 0.0001
51.1 NS
59.2 NS
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Table 2. Comparison of the baseline variables between patients who
were receiving once or twice dialysis per week and those of thrice
dialysis per week at the entry to the study (January 1991)
Frequency of dialysis per week
Once & twice Thrice
Clinical N = 192 N = 994 P value
Age years 56.1 (1.2) 51.6 (0.4) 0.0006
Duration of HD months 29.0 (2.7) 68.8 (1.6) 0.0001
Dose of dialysis m2hr/W 10.3 (0.2) 19.8 (0.2) 0.0001
Body height meters 1.54 (0.006) 1.57 (0.003) 0.0001
Body weight kg
Body mass index kg/rn2
49.1 (0.7)
20.7 (0.2)
53.8 (0.3)
21.8 (0.1)
0.0001
0.0001
Systolic BP mm Hg 153.9 (1.6) 151.1 (0.8) NS
Diastolic BP mm Hg 78.8 (1.0) 81.2 (0.4) 0.027
Total protein g/dl 6.6 (0.04) 6.5 (0.02) NS
Serum albumin g/dl 3.9 (0.04) 3.9 (0.02) NS
Total cholesterol mg/cl! 171.5 (3.2) 171.0 (1.3) NS
Triglyceride mg/dl 136.6 (5.9) 166.9 (3.9) 0.0001
BUN mg/dl 89.4 (1.6) 85.1 (0.6) 0.012
Serum creatinine mg/dl 11.8 (0.3) 13.4 (0.1) 0.0001
Serum uric acid mg/dl 8.3 (0.1) 8.2 (0.1) NS
Smoker % 18.2 24.5 NS
Drinker % 13.5 21.6 0.011
Diabetes mellitus % 23.4 16.5 0.021
Antihypertensives % 52.6 51.5 NS
Male % 47.9 60.1 0.002
Death rate % 32.8 28.1 NS
Patients who received renal transplantation (N = 45) or were trans-
ferred outside Okinawa (N = 12) during the study period were excluded.
Numbers in parentheses denote SEM. Abbreviations are: HD, hemodialy-
sis; BP, blood pressure; BUN, blood urea nitrogen; NS, not significant.
Duration of HD refers to how long the patients had been on dialysis prior
to entry into the study.
Table 3. Relationship between serum albumin level and blood pressure
Baseline serum albumin g/dl
<3.5 3.5—3.9 4.0—4.4 4.5
N = 206 N = 501 N = 373 N = 139
SBP mm Hg
mean 152.4 151.2 151.7 151.0
SEM 1.8 1.1 1.2 1.8
DBPmm Hg
mean 78.3 80.2 82.1 84.1
SEM 0.9 0.6 0.6 1.2
Renal transplantation 2 (1.0%) 12 (2.4%) 20 (5.4%) 11(7.9%)
Transferred outside 3 (1.5%) 3 (0.6%) 2 (0.5%) 4 (2.9%)
Okinawa
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood
pressure.
Table 6 shows the causes of death in relation to age at start of
the study. The leading cause of death was different in each age
group. In the 0 to 44 and 45 to 54 year-old groups, vascular disease
was the most common causes of death. In the 55 to 64 year-old
group, cardiac disease was the most common cause. Whereas in
the older than 65-year-old group, the most common cause was
withdrawal from dialysis.
Table 7 summarizes the results of multiple logistic analysis. The
adjusted odds ratio (95% confidence interval) for death was 0.84
(0.71 to 0.99) for diastolic blood pressure and 0.77 (0.64 to 0.91)
for serum albumin. The variables included were sex, age, duration
of dialysis, diabetes mellitus, smoking, dose of dialysis, body mass
Table 4. Number of total and deceased patients in each stratum of
systolic blood pressure (SBP), diastolic blood pressure (DBP), and
mean arterial pressure (MAP)
Patients
Exposed Died
Death
rate
Age of
patients
mean (SCM)
SBP mm Hg
—79 3 2 0.67 66.9 (6.9)
80—99 10 2 0.20 54.7 (2.7)
100—119 58 15 0.26 54.0 (2.0)
120—139 227 56 0.25 52.9 (0.9)
140—159 404 102 0.25 51.8 (0.7)
160—179 353 111 0.31 52.1 (0.8)
180— 188 54 0.29 52.1 (1.0)
DBPmm Hg
—69 154 61 0.40 58.7 (1.2)
70—79 267 93 0.35 56.8 (0.9)
80—89 426 108 0.25 51.9 (0.6)
90—99 232 58 0.25 50.1 (0.9)
100— 164 22 0.13 43.0 (1.0)
MAP mm Hg
—89 178 59 0.33 56.0 (1.2)
90—99 235 68 0.29 55.1 (0.9)
100—109 374 111 0.30 52.6 (0.7)
110—119 245 63 0.26 51.5 (0.9)
120— 211 41 0.19 46.5(0.9)
Age of patient was calculated at start of study (Jan. 1, 1991). Abbrevi-
ation SEM is standard error of mean. Follow-up period was 1991 through
1995.
Table 5. Causes of death and baseline serum albumin
Cause of death
Baseline serum albumin g/dl
Total<3.5 3.5—3.9 4.0—4.4 4.5
Infection 19 (18.6) 26 (17.2) 12 (18.5) 5 (22.7) 62 (18.2)
Withdrawal 30 (29.4) 16 (10.6) 9 (13.8) 1(4.5) 56 (16.5)
Cardiac 20 (19.6) 43 (28.5) 9 (13.8) 6 (27.3) 78 (22.9)
Sudden death 7 (6.9) 10 (6.6) 4 (6.2) 4 (18.2) 25 (7.4)
Vascular 15 (14.7) 27 (17.9) 22 (33.8) 3 (13.6) 67 (19.7)
Others 11(10.8) 29 (18.2) 9 (13.8) 3 (13.6) 52 (15.3)
Number of
deaths 102 (100) 151 (100) 65 (100) 22 (100) 340 (100)
exposed 206 501 373 139 1,219
Death rate (49.5) (30.1) (17.4) (15.8) (27.9)
Follow-up period was 1991 through 1995. Total number of deaths was
342. Two patients had no baseline serum albumin data. Parentheses
denote percentage.
index, serum creatinine, systolic and diastolic blood pressure,
serum albumin. The crude death rate was highest as 57.3% in a
subgroup of patients (N = 89) with low serum albumin (<3.5 g/dl)
and low diastolic blood pressure (<80 mm Hg), and lowest as
11.1% in a subgroup of patients (N = 63) with high serum
albumin (4.5 g/dl) and high diastolic blood pressure mm
Hg).
Discussion
Hypertension is usually present at the initiation of dialysis
therapy. With the start of regular hemodialysis, most patients
become normotensive by attaining dry weight. However, few
studies have investigated the significance of control of blood
pressure in maintenance dialysis patients [12]. Charra et al [2, 3]
demonstrated very good control of blood pressure and excellent
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Fig. 2. Survival curves, calculated by method of Kaplan-Meier, for each
baseline level of serum albumin. Follow-up period was 1991 through 1995.
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prognosis by prescribing a long slow dialysis. We [1, 4] and others
[5—7, 13] have been prescribing a dose of dialysis lower than that
of Charra et al. Recently, the number of older and sicker patients
accepted for dialysis has been increasing [1, 7]. In these patients,
rapid ultrafiltration may cause a premature drop in blood pressure
before they reach dry weight. The use of shortened dialysis and
noncompliance in adult dialysis patients [14] may further increase
the incidence of hypertension and deteriorate nutritional status.
The essential hypertension population consists of those of
salt-sensitive and non-salt-sensitive subjects. Manipulation of salt
intake within the range of 2 to 30 g/day results in little or no
observable change for the general population as a whole [15].
Therefore, assuming that all dialysis patients are salt sensitive is
not realistic [6, 121. In the well known paper of Vertes et al [13],
blood pressure was followed for less than six months, a relatively
short period. Reported blood pressure levels were approximately
150 mm Hg in SBP and 80 to 90 mm Hg in DBP, which agrees
with our data (Tables 3 and 4). Moreover, the relationship
between volume and vasoconstrictor factors is complex [16—18].
Potent antihypertensive drugs have been developed recently;
Cause of death
Age at start of study years
Total0—44 45—54 55—64 65+
Infection 5 (13.2) 8 (16.7) 15 (15.6) 34 (21.2) 62 (18.1)
Withdrawal 2 (5.3) 5 (10.4) 8 (8.3) 41(25.6) 56 (16.4)
Cardiac 10 (26.3) 5 (10.4) 29 (30.2) 34 (21.3) 78 (22.8)
Sudden death 5 (13.2) 5 (10.4) 6 (6.3) 10 (6.3) 26 (7.6)
Vascular 15 (39.4) 19 (39.6) 18 (18.8) 15 (9.4) 67 (19.6)
Others 1(2.6) 6 (12.5) 20 (20.8) 26 (16.2) 53 (15.5)
Number of
deaths 38(100) 48(100) 96(100) 160(100) 342(100)
exposed 433 268 284 258 1,243
Death rate 8.8% 17.9% 33.8% 62.0% 27.5%
therefore, our patient population included no cases of bilateral
nephrectomy for the control of blood pressure.
Our results suggest that the optimal level of blood pressure
associated in terms of death rate is higher in dialysis patients than
in the general population [8, 19—21]. Erroa et al [221 reported that
low DBP was associated with visceral and somatic malnutrition as
well as a high mortality rate in dialysis patients. Relative hypo-
tension was a potent marker of mortality in dialysis patients [10].
Hypotension may reflect both the severity of disease, ischemic
heart disease and/or cardiomyopathy, and the intensity of therapy
used to treat the disease. A close correlation was observed
between DBP and serum albumin or patient's age (Tables 3 and
4). Serum albumin is a strongest predictors of death in dialysis
patients [4, 5, 23, 24], and even in patients at baseline who are
starting dialysis therapy [25]. Therefore, multiple logistic analysis
is required in order to investigate the role of blood pressure
adjusted with other confounding predictors of death. In a short-
term follow-up study, the effect of blood pressure on mortality was
not found to be significant [4, 6].
Dialysis patients are highly selected and have multiple risk
factors of cardiovascular disease. They are often malnourished [4,
5, 23, 24] and have comorbid conditions in addition to renal
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Fig. 4. Survival curves, calculated by method of Kaplan-Meier, for each
baseline level of diastolic blood pressure. Follow-up period was 1991 though
1995.
Table 6. Causes of death and age at start of study
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Fig. 3. Survival curves, calculated by method of Kaplan-Meier, for each
baseline level of systolic blood pressure. Follow-up period was 1991 through
1995.
Follow-up period was 1991 through 1995. Age was calculated on
January 1, 1991. Parentheses denote percentage.
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Tabie 7. Multiple logistic analysis of clinical predictors of death in
cohort of chronic hemodialysis
Odds
95% confide
ratio
nce intenal
Not adjusted Adjusteda
Systolic blood pressure 1.09 1.12(vs. less than 119 mm Hg) (0.97—1.22) (0.95—1.33)
20 mm Hg increments
Diastolic blood pressure 0.73 0.84
(vs. less than 69 mm Hg) (0.65-0.82) (0.71—0.99)
10 mm Hg increments
Serum albumin 0.53 0.77
(vs. <3.5 g/dl) (0.45—0.61) (0.64—0.91)
Follow-up period was 1991 through 1995.
a Adjusted for other potential predictors of death such as sex, age,
duration of dialysis, diabetes mellitus, smoking, dose of dialysis, body mass
index, serum creatinine, and variables in table.
failure [7, 26—28] at the initiation of dialysis. In our cohort of
dialysis patients, systolic blood pressure was not observed to
increase with age [29]. A similar phenomenon was reported in the
inhabitants of undeveloped countries, agreeing with the estab-
lished clinical effects of salt restriction [301. However, lack of
obesity and weight gain with advance of age and change of lifestyle
were other possible explanations [30]. Obviously, the lifestyle of
dialysis patients is quite different from that of the general
population.
Elevated DBP, but not decreased DBP, was associated with a
high mortality rate in the Diaphane study [23]. The background of
the present patient population was different in several ways. First,
the duration of dialysis is different. The mean duration of
hemodialysis in the present study was approximately 60 months at
the start of the study, so many high-risk patients may have died
before entering the study. Actually, the peak hazard for cardio-
vascular death was less than four years of dialysis [111. Second, our
study population included a higher proportion of diabetic pa-
tients, who are known to have poor survival [1], Third, a precise
relationship between blood pressure and nutritional status was
not shown in their study.
Calcium channel blockers were the most frequently used anti-
hypertensive drugs in our registry [29], and have the distinct
advantage of short duration of action and rapid onset when
administered sublingually [31]. Although the dialysance of these
drugs is not well known [32], no serious side effects were noted,
except for occasional hypotension. ACE inhibitors may cause
anaphylactoid reaction with the use of PAN membrane dialyzers
[33], but we have experienced no such cases.
The use of erythropoietin may increase blood pressure [34]. We
do not know the incidence of hypertension in relation to the use
of antihypertensive drugs before the era of erythropoietin in our
registry. Erythropoietin was not funded for general clinical use in
Japan until April 1990. No case of death related to the hyperten-
sive effect of erythropoietin occurred during the observation
period.
In the present cohort study, the baseline blood pressure was
measured immediately prior to the first dialysis session in 1991.
Correlation of the one-point blood pressure and the one month
average blood pressure was excellent in both systolic and diastolic
blood pressures [29]. Furthermore, we evaluated the determinants
of blood pressure by stepwise regression and univariate analysis.
For systolic blood pressure, a positive association was found with
male, diabetes mellitus, total cholesterol, use of antihypertensives,
year at start of dialysis, and negative associations were age,
triglyceride, total protein. For diastolic blood pressure, a positive
association was found with male, total cholesterol, use of antihy-
pertensives, and dose of dialysis, and negative associations were
age and triglyceride.
The use of baseline blood pressure is recommended over the
use of time-averaged blood pressure in prospective studies [35].
The dose of antihypertensive drugs immediately preceding dialysis
may be reduced or omitted to minimize the risk of hypotension
during the procedure [311. Instructions given to patients about
taking antihypertensive medication before hemodialysis varied
among physicians in our multi-center study. Using 48-hour blood
pressure monitoring, Cheigh et al reported no apparent difference
in blood pressure prior to hemodialysis and mean blood pressure
in 53 chronic dialysis patients [12]. Hypertension was found to be
inadequately controlled.
In order to perform regular hemodialysis, stable hemodynamics
and good blood access are mandatory. Patients with low DBP may
show unstable hemodynamics during dialysis, and blood access
may not be adequate to perform regular dialysis. Moreover,
physicians in charge of the dialysis session may choose a higher
blood pressure [31] and not increase the ultrafiltration rate,
intending to perform "asymptomatic dialysis." This practice may
lead to fluid overload, even in patients with normal cardiac
function. The clinical significance of these practices need to be
studied further. Blood access thrombosis frequently occurs in
patients with low serum albumin [6]. Hypoalbuminemia is poten-
tially reversible risk factor of ischemic heart disease [36].
The present results do not exclude the importance of blood
pressure control [37—40], indeed, hypertension is a strong predic-
tor of stroke in this patients population [38]. The deleterious
effect of lowering blood pressure in treated hypertensive patients
is known as the J curve phenomenon [8]. Preceding illness is
thought to lower blood pressure or DBP, precipitating death from
coronary heart disease [8] and probably cardiomyopathy [10]. The
causes of skewed relationship between the crude death rate and
blood pressure in chronic dialysis patients were not determined in
this study. We suspect that the high prevalence of cardiovascular
disease [26—28] is playing a role, at least partly. The best survival
rate in dialysis patients was obtained by control of both nutritional
status and blood pressure [2]. Regimens of antihypertensive
treatment and dialysis prescription may need to be re-evaluated,
especially in patients with hypoalbuminemia and low DBP.
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